Publications by authors named "Djamila Bouharati"
J Chemother
December 2024
Article Synopsis
- Anti-PD-1/PD-L1 combined with chemotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC), but its effectiveness in older patients is uncertain.
- A meta-analysis of ten phase III trials, involving over 3,600 patients aged 65 and older, showed that this treatment significantly improves overall survival (OS) and progression-free survival (PFS) for patients over 65.
- However, for patients over 75, the survival benefit was not statistically significant, making it hard to draw firm conclusions for this age group due to a smaller sample size.
